Alkermes plc (NASDAQ:ALKS) SVP Sells $106,489.35 in Stock

Alkermes plc (NASDAQ:ALKS) SVP Christian Todd Nichols sold 3,333 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $31.95, for a total transaction of $106,489.35. Following the sale, the senior vice president now owns 89,542 shares in the company, valued at approximately $2,860,866.90. This trade represents a 3.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Christian Todd Nichols also recently made the following trade(s):

• On Tuesday, June 10th, Christian Todd Nichols sold 3,334 shares of Alkermes stock. The stock was sold at an average price of $31.09, for a total value of $103,654.06.

Alkermes Trading Down 1.3%

Shares of NASDAQ:ALKS opened at $30.78 on Friday. The firm has a 50 day simple moving average of $29.63 and a 200-day simple moving average of $31.02. Alkermes plc has a twelve month low of $22.90 and a twelve month high of $36.45. The company has a market capitalization of $5.08 billion, a PE ratio of 14.18, a P/E/G ratio of 2.20 and a beta of 0.47.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings results on Thursday, May 1st. The company reported $0.13 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.19). Alkermes had a net margin of 23.57% and a return on equity of 30.80%. The company had revenue of $306.51 million during the quarter, compared to analysts’ expectations of $307.53 million. During the same period last year, the firm earned $0.43 earnings per share. Alkermes’s revenue was down 12.6% on a year-over-year basis. As a group, equities research analysts predict that Alkermes plc will post 1.31 EPS for the current fiscal year.

Institutional Trading of Alkermes

Several institutional investors and hedge funds have recently made changes to their positions in ALKS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Alkermes by 0.3% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 100,032 shares of the company’s stock worth $2,877,000 after buying an additional 311 shares during the period. CIBC Asset Management Inc increased its holdings in shares of Alkermes by 4.4% in the 4th quarter. CIBC Asset Management Inc now owns 9,155 shares of the company’s stock valued at $263,000 after acquiring an additional 384 shares during the period. Quantbot Technologies LP increased its holdings in shares of Alkermes by 54.5% in the 1st quarter. Quantbot Technologies LP now owns 1,091 shares of the company’s stock valued at $36,000 after acquiring an additional 385 shares during the period. Hohimer Wealth Management LLC raised its position in Alkermes by 3.8% in the 1st quarter. Hohimer Wealth Management LLC now owns 12,362 shares of the company’s stock valued at $408,000 after purchasing an additional 450 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its position in Alkermes by 3.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 12,352 shares of the company’s stock valued at $408,000 after purchasing an additional 451 shares during the last quarter. 95.21% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently commented on ALKS shares. Wall Street Zen cut Alkermes from a “strong-buy” rating to a “buy” rating in a research note on Monday, May 5th. Cantor Fitzgerald upgraded Alkermes to a “strong-buy” rating in a research note on Tuesday, May 13th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Alkermes from $40.00 to $52.00 and gave the stock a “buy” rating in a research note on Thursday, March 27th. HC Wainwright reiterated a “neutral” rating on shares of Alkermes in a research note on Friday, May 2nd. Finally, Needham & Company LLC began coverage on shares of Alkermes in a report on Wednesday, May 28th. They set a “buy” rating and a $45.00 price target for the company. Four analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $38.85.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.